EMA: Five-Year Regulatory Network Strategy Still ‘Valid And Relevant’ At Midway Point

A report by the European Medicines Agency outlines the progress that has been made so far in delivering on the key pillars of its five-year network strategy, proposed in 2020, and lists areas where work is ongoing.

European Union flag with covid-19 coronavirus in background — Antimicrobial resistance was a priority area within the European medicines agencies network strategy • Source: Shutterstock/Hyserb

Tackling medicines shortages, improving regulatory sustainability, and reducing the threat of antimicrobial resistance were among the six priority areas of a five-year plan published by the European Medicines Agency (EMA) and EU Heads of Medicines Agencies (HMA) at the end of 2020.

The European medicines agencies network strategy (EMANS) reached its halfway point this June, and according to a midterm report...